Integreted Filling Financials for the quarter ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Phaarmasia Ltd submitted its Q1 FY26 unaudited financial results to BSE. Revenue from operations stood at Rs. 687.36 lakhs, down about 17% from Rs. 829.19 lakhs in the same quarter last year. The company posted a net profit of Rs. 27.02 lakhs (EPS Rs. 0.40), a sharp recovery from the Rs. 52.50 lakh loss in the preceding Q4 FY25. Total expenses were kept in check at Rs. 687.58 lakhs against total income of Rs. 718.88 lakhs. The statutory auditor issued a clean (unmodified) limited review report with no qualifications. The company also reported zero outstanding loans, debt or defaults, and confirmed single-segment operations in pharma.
Sequential turnaround into profit is a positive sign, but the year-on-year drop in revenue suggests demand or pricing weakness that investors should watch. With no debt on the books and a clean auditor report, near-term financial risk appears limited.